Navidea Biopharmaceuticals Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Navidea Biopharmaceuticals has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Joshua Wilson	Director	1.3yrs	US$17.72k	0.030% $ 1.5k
Siamon Gordon	Member of Scientific Advisory Board	no data	no data	no data
Charles Mills	Member of Scientific Advisory Board	no data	no data	no data
John Scott	Vice Chairman	2.5yrs	US$110.15k	31.77% $ 1.6m
Dana Moss	Independent Director	less than a year	no data	0.87% $ 43.7k
Jill Stefanelli	Independent Director	less than a year	no data	0.94% $ 47.4k

1.0yrs

Average Tenure

46yo

Average Age

Experienced Board: NO1A's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Navidea Biopharmaceuticals Management

Management criteria checks 0/4

Key information

Recent management updates

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023

Navidea Biopharmaceuticals, Inc. Announces Executive Changes

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Navidea Biopharmaceuticals, Inc. Announces Board Changes

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Recent updates

Navidea Biopharmaceuticals, Inc. Files Form 15

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023

Navidea Biopharmaceuticals Requests Oral Hearing with NYSE Hearing Panel

NYSE American Determines to Commence Proceedings to Delist the Common Stock of Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. Announces Executive Changes

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Navidea Biopharmaceuticals Proposes Reverse Stock Split, Stock-For-Debt Swap to End Its Threat of De-Listing

New major risk - Shareholder dilution

High number of new and inexperienced directors

Navidea Biopharmaceuticals Receives NYSE American Notice

Navidea Biopharmaceuticals, Inc. Announces Board Changes

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

Navidea Biopharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.56 loss per share (vs US$0.40 loss in FY 2021)

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Cancer Immunotherapy Pipeline

Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc. Files Appeal in CRG Case

Navidea Biopharmaceuticals, Inc. Announces 50th Participant Enrolled in the its Phase 3 Trial in Rheumatoid Arthritis

High number of new and inexperienced directors

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Navidea Biopharmaceuticals, Inc. Announces Results from the Completed NAV3-31 Phase 2B Clinical Study as Well as the Preliminary Results of Its Ongoing NAV3-32 Phase 2B Study At Annual Meeting of the American College of Rheumatology

Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics Inc. Announces Court Made an Oral Ruling from Bench in Open Court At the Conclusion of the Trial in Case No. 2018-24442-151

Navidea Biopharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $14.2 million.

Second quarter 2022 earnings released: US$0.099 loss per share (vs US$0.092 loss in 2Q 2021)

Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

First quarter 2022 earnings released: US$0.099 loss per share (vs US$0.11 loss in 1Q 2021)

High number of new and inexperienced directors

Navidea Biopharmaceuticals, Inc. Announces Positive Preliminary Results of its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India

Navidea Biopharmaceuticals Receives Acceptance Letter from Nyse American

Navidea Biopharmaceuticals Announces Executive Changes

Navidea Biopharmaceuticals Announces Receipt of Noncompliance Notice from NYSE American

Forecast to breakeven in 2024

Navidea Biopharmaceuticals, Inc. Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Programram

Navidea Biopharmaceuticals, Inc. Provides Update on Litigation with Capital Royalty Partners II L.P

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.13 loss in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

Independent Director Claudine Bruck has left the company

Independent Chairman of the Board Sarah Rouan has left the company

Second quarter 2021 earnings released: US$0.092 loss per share (vs US$0.11 loss in 2Q 2020)

Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

John K. Scott Requests Navidea Biopharmaceuticals to Appoint Two Additional Members to the Board

Forecast breakeven pushed back to 2024

Chief Business Officer has left the company

Full year 2020 earnings released: US$0.48 loss per share (vs US$0.76 loss in FY 2019)

Navidea Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding

New 90-day high: €2.52

Navidea Biopharmaceuticals, Inc. Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

New 90-day low: €1.83

Revenue beats expectations

Third quarter 2020 earnings released: US$0.13 loss per share

Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients from Its Ongoing Phase 2B Study in Rheumatoid Arthritis

New 90-day low: €1.92

New 90-day low: €2.16

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation At the American College of Rheumatology Annual Meeting

New 90-day low: €2.24

New 90-day low - €2.26

First half earnings released

Navidea Biopharmaceuticals, Inc. announced that it has received $1 million in funding from Jubilant Pharma Limited

New 90-day high - €4.30

CEO

Board Members

Average Tenure